BRIEF-Catabasis Pharma provides edasalonexent and rare disease pipeline updates at investor day

* Catabasis Pharma- Top-line safety and efficacy results

from placebo-controlled portion of movedmd phase 2 trial are

expected in first half of Q1 2017

Read more